The Power List 2020 – Small Molecules
General Manager at Pfizer CentreOne
JoyL joined Pfizer more than 20 years ago and assumed the role of Pfizer CentreOne’s general manager in 2019. JoyL contributes to the industry by serving on the board of Pharma and Biopharma Outsourcing Association, a non-profit association that represents the needs of CDMOs in the US and is a frequent speaker at industry events and a published author.
Which people have inspired you?
The patients that I worked with as a nursing assistant while I was in college were a huge source of inspiration. Taking care of patients in a hospital or a nursing home setting really puts into perspective what it means to develop and manufacture medicines when you see how powerful they can be.
What is the next big thing for the small molecule field?
I am excited to deliver on the innovative promise that small molecules are expected to bring to key therapeutic areas. The growth of highly potent APIs and the combined use of small molecules with ADCs represents an exciting opportunity for pharma and gives patients hope. Given their evolving potency and complexity, the life science sector will continue to demand that we work alongside other areas of industry to deliver new specialized technologies so that targeted precision medicine is available when patients need it most.